132 related articles for article (PubMed ID: 30326767)
21. [New approaches to antioxidant therapy in multiple sclerosis].
Odinak MM; Bisaga GN; Zarubina IV
Zh Nevrol Psikhiatr Im S S Korsakova; 2002; Suppl():72-5. PubMed ID: 12418396
[TBL] [Abstract][Full Text] [Related]
22. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
Calabresi PA; Radue EW; Goodin D; Jeffery D; Rammohan KW; Reder AT; Vollmer T; Agius MA; Kappos L; Stites T; Li B; Cappiello L; von Rosenstiel P; Lublin FD
Lancet Neurol; 2014 Jun; 13(6):545-56. PubMed ID: 24685276
[TBL] [Abstract][Full Text] [Related]
23. The role of endogenous antiradical protective system in multiple sclerosis.
Davitashvili D; Beridze M; Shakarishvili R; Kiziria M; Sanikidze T
Georgian Med News; 2012 Apr; (205):11-9. PubMed ID: 22665726
[TBL] [Abstract][Full Text] [Related]
24. Health care situation of patients with relapsing-remitting multiple sclerosis receiving immunomodulatory therapy: a retrospective survey of more than 9000 German patients with MS.
Mäurer M; Dachsel R; Domke S; Ries S; Reifschneider G; Friedrich A; Knorn P; Landefeld H; Niemczyk G; Schicklmaier P; Wernsdörfer C; Windhagen S; Albrecht H; Schwab S;
Eur J Neurol; 2011 Aug; 18(8):1036-45. PubMed ID: 21199183
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness of natalizumab vs fingolimod for the treatment of relapsing-remitting multiple sclerosis: analyses in Sweden.
O'Day K; Meyer K; Stafkey-Mailey D; Watson C
J Med Econ; 2015 Apr; 18(4):295-302. PubMed ID: 25422991
[TBL] [Abstract][Full Text] [Related]
26. Second-line therapy with fingolimod for relapsing-remitting multiple sclerosis in clinical practice: the effect of previous exposure to natalizumab.
Bianco A; Patanella AK; Nociti V; Marti A; Frisullo G; Plantone D; De Fino C; Fetta A; Batocchi AP; Rossini PM; Mirabella M
Eur Neurol; 2015; 73(1-2):57-65. PubMed ID: 25402749
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing-remitting multiple sclerosis in Argentina.
Carrá A; Onaha P; Luetic G; Burgos M; Crespo E; Deri N; Halfon M; Jaacks G; López A; Sinay V; Vrech C
Eur J Neurol; 2008 Apr; 15(4):386-93. PubMed ID: 18353125
[TBL] [Abstract][Full Text] [Related]
28. Serum levels of IL-17A in patients with relapsing-remitting multiple sclerosis treated with interferon-β.
Bălaşa R; Bajko Z; Huţanu A
Mult Scler; 2013 Jun; 19(7):885-90. PubMed ID: 23207971
[TBL] [Abstract][Full Text] [Related]
29. Immunomodulatory effects of IFN-beta1a treatment alone or associated with pentoxifylline in patients with relapsing-remitting multiple sclerosis (RRMS).
Pede PD; Visintini D; Telera A; Cucurachi L; Campanini C; Immovilli P; Vescovini R; Sansoni P
J Interferon Cytokine Res; 2005 Aug; 25(8):485-9. PubMed ID: 16108731
[TBL] [Abstract][Full Text] [Related]
30. Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis.
Zivadinov R; Dwyer MG; Hussein S; Carl E; Kennedy C; Andrews M; Hojnacki D; Heininen-Brown M; Willis L; Cherneva M; Bergsland N; Weinstock-Guttman B
Mult Scler; 2012 Aug; 18(8):1125-34. PubMed ID: 22194217
[TBL] [Abstract][Full Text] [Related]
31. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients.
Río J; Rovira A; Tintoré M; Huerga E; Nos C; Tellez N; Tur C; Comabella M; Montalban X
Mult Scler; 2008 May; 14(4):479-84. PubMed ID: 18562504
[TBL] [Abstract][Full Text] [Related]
32. Daclizumab for the treatment of relapsing-remitting multiple sclerosis.
Herwerth M; Hemmer B
Expert Opin Biol Ther; 2017 Jun; 17(6):747-753. PubMed ID: 28286970
[TBL] [Abstract][Full Text] [Related]
33. Cognitive function did not improve after initiation of natalizumab treatment in relapsing-remitting multiple sclerosis. A prospective one-year dual control group study.
Sundgren M; Piehl F; Wahlin Å; Brismar T
Mult Scler Relat Disord; 2016 Nov; 10():36-43. PubMed ID: 27919496
[TBL] [Abstract][Full Text] [Related]
34. A discrete event simulation to model the cost-utility of fingolimod and natalizumab in rapidly evolving severe relapsing-remitting multiple sclerosis in the UK.
Montgomery SM; Maruszczak MJ; Slater D; Kusel J; Nicholas R; Adlard N
J Med Econ; 2017 May; 20(5):474-482. PubMed ID: 28008769
[TBL] [Abstract][Full Text] [Related]
35. Cost-utility of fingolimod compared with dimethyl fumarate in highly active relapsing-remitting multiple sclerosis (RRMS) in England.
Maruszczak MJ; Montgomery SM; Griffiths MJ; Bergvall N; Adlard N
J Med Econ; 2015; 18(11):874-85. PubMed ID: 26055952
[TBL] [Abstract][Full Text] [Related]
36. Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis.
Lizak N; Lugaresi A; Alroughani R; Lechner-Scott J; Slee M; Havrdova E; Horakova D; Trojano M; Izquierdo G; Duquette P; Girard M; Prat A; Grammond P; Hupperts R; Grand'Maison F; Sola P; Pucci E; Bergamaschi R; Oreja-Guevara C; Van Pesch V; Ramo C; Spitaleri D; Iuliano G; Boz C; Granella F; Olascoaga J; Verheul F; Rozsa C; Cristiano E; Flechter S; Hodgkinson S; Amato MP; Deri N; Jokubaitis V; Spelman T; Butzkueven H; Kalincik T;
J Neurol Neurosurg Psychiatry; 2017 Mar; 88(3):196-203. PubMed ID: 27683916
[TBL] [Abstract][Full Text] [Related]
37. Association between soluble L-selectin and anti-JCV antibodies in natalizumab-treated relapsing-remitting MS patients.
Basnyat P; Hagman S; Kolasa M; Koivisto K; Verkkoniemi-Ahola A; Airas L; Elovaara I
Mult Scler Relat Disord; 2015 Jul; 4(4):334-8. PubMed ID: 26195052
[TBL] [Abstract][Full Text] [Related]
38. The combination of cyclophosphamide plus interferon beta as rescue therapy could be used to treat relapsing-remitting multiple sclerosis patients-- twenty-four months follow-up.
Reggio E; Nicoletti A; Fiorilla T; Politi G; Reggio A; Patti F
J Neurol; 2005 Oct; 252(10):1255-61. PubMed ID: 15940386
[TBL] [Abstract][Full Text] [Related]
39. [Efficacy and safety of fingolimod in routine clinical practice in patients with relapsing-remitting multiple sclerosis in Spain: an intermediate analysis of the MS NEXT study].
Mallada-Frechin J; Meca-Lallana V; Barrero F; Martinez-Gines ML; Marzo-Sola ME; Ricart J; Garcia E; En Representacion de Los Investigadores Del Estudio Ms Next ERLIDEMN
Rev Neurol; 2018 Sep; 67(5):157-167. PubMed ID: 30047118
[TBL] [Abstract][Full Text] [Related]
40. The IFN-β 1b effect on Cu Zn superoxide dismutase (SOD1) in peripheral mononuclear blood cells of relapsing-remitting multiple sclerosis patients and in neuroblastoma SK-N-BE cells.
Damiano S; Sasso A; De Felice B; Terrazzano G; Bresciamorra V; Carotenuto A; Orefice NS; Orefice G; Vacca G; Belfiore A; Santillo M; Mondola P
Brain Res Bull; 2015 Sep; 118():1-6. PubMed ID: 26327496
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
